Work

Chemo-RaST with bortezomib inhibits multiple myeloma relapse

Year: 2025

Type: article

Abstract: Tracer doses of long-lived ⁸⁹Zr for sustained photosensitizer activation, combined with subtherapeutic bortezomib, represent a clinically translatable strategy to limit off-target toxicity, prevent relapse, and overcome therapy resistance in multiple myeloma.

Source: Theranostics

DOI: 10.7150/thno.111508

Authors: Anchal Ghai, Alexander Zheleznyak, Christopher Egbulefu, Nicole Blasi, Kvar Black, Rui Tang, Matthew L Cooper, Kiran Vij, Ravi Vij, John DiPersio, Monica Shokeen, Samuel Achilefu

Institutions: Washington University in St. Louis, The University of Texas Southwestern Medical Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,671

Funders: National Institutes of Health, National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering

Awards: Multispectral Optoacoustic Tomography (MSOT) System, Imaging Goggles for Fluorescence-Guided Surgery, G3568507935, G3841404249, MOLECULAR PROBES AND METHODS FOR FLUORESCENCE LIFETIME TOMOGRAPHY AND MICROSCOPY, IVIS Spectrum CT Preclinical In Vivo Imaging System, G7298050710, G7311593635, TARGETING AML-STROMAL INTERACTIONS, RETARGETING AGENTS TO TREAT AML, Cancer Center Support Grant

OpenAlex ID: W4414269380

FWCI: 0.635

Cites:

Cited by: 1

Related to: